STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.

≈